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ABSTRACT
Interleukin-15 Overexpression Attenuates Muscle Fatigue Associated with Murine
EO771 Mammary Tumors
Joseph F. Bohlen
Severe muscle wasting and muscle dysfunction (cachexia) are considered
incurable complications associated with a wide variety of chronic diseases. This loss of
function and severe wasting causes an increase in fatigue in cancer patients, leading to
reduced motivation for daily activities, further reducing prognosis for recovery in these
patients leading to a severe increase in morbidity. Recent work from our lab suggests
Interleukin-15 (IL-15) induces a pro-oxidative state in the muscle, reducing fatigue and
promoting a more oxidative phenotype. One proposed mechanism behind this is the
observation that IL-15 promotes mitochondrial biogenesis, lending more mitochondria
for oxidative metabolic processes. Therefore, we tested the hypothesis that orthotopic
implantation of E0771 mammary tumor cells would induce greater muscle fatigue in
tumor bearing mice and that muscle-specific IL-15 overexpression would attenuate this
cancer-induced increase in muscle fatigability. In our initial study performed in C57BL/6
wild type mice, 4 weeks of E0771 mammary tumor growth induced a significant
increase in muscle fatigue along with a significant reduction in mtDNA content, while 2
weeks of growth had no effects on muscle function. This was associated with lesser
mRNA expression for IL-15 and IL-15Rα in the muscles of tumor bearing mice.
Subsequently, we induced E0771 mammary tumors in muscle-specific IL15 overexpressing mice and littermate control mice for 4 weeks. While muscle fatigue was
significantly greater in tumor-bearing littermate control mice compared to littermate
control mice without tumors, muscle fatigue was attenuated in muscles from tumorbearing IL15 over-expressing mice compared to IL15TG mice without tumors. These
data highlight IL-15 a potential therapy for reducing fatigue in the weakened/cachectic
state. Along with this, IL-15 has been well published with promoting Natural Killer (NK)
cell cytotoxicity, increasing immunosurveillance and promoting overall T cell
development. This, combine with the pro-oxidative environment make IL-15 an ideal
therapy for cancer cachexia. Future studies can look at potential dosing requirements
of IL-15 before moving on to clinical trials.
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Interleukin-15 Overexpression Attenuates Muscle Fatigue
Associated with Murine EO771 Mammary Tumors
Joseph F. Bohlen
Division of Exercise Physiology, West Virginia University School of Medicine

Chapter 1.
Introduction:
Severe muscle wasting and muscle dysfunction (cachexia) are considered
incurable complications associated with a wide variety of chronic diseases. Cachexia
significantly decreases the quality of life for cancer patients, more specifically; it leads to
an overall poor prognosis for recovery and accounts for ~40-50% of cancer patient
morbidity. (1) Cachexia is classified by a severe loss of body weight due to a significant
loss of fat and muscle mass. More pertinent to this study, however, is the muscular
dysfunction (fatigue) that is associated with this disease. Cachexia is considered a
factor in determining cancer-related death, yet no direct experimental evidence has
surfaced to solidify this hypothesis. (2) It has been well documented that standard
nutritional approaches do not mediate muscle wasting in regards to cancer. (3,4) In lieu
of this, significant focus has shifted towards other strategies for reducing cachexia in
cancer patients in order to improve prognosis.

Cancer cachexia is believed to induce muscle wasting, along with muscle
dysfunction eliciting significant fatigue and reduced motivation for daily activities. This

2

fatigue is thought to be derived from alterations in skeletal muscle contractile machinery
along with alterations in mitochondrial function. Indeed, cachectic muscles show a shift
in fatigue resistance, exhibiting a more glycolytic and fatigable phenotype in muscle
fibers. Recent data from our lab suggest IL15 might be an excellent therapy, with
potential to reduce the outcomes of cancer cachexia. For example, recently our pilot
studies have shown that IL-15 promotes a more oxidative/fatigue resistant phenotype.
In addition, our IL15 transgenic overexpressor mice have shown marked increases in
markers of mitochondrial biogenesis along with increases in cage activity due to higher
levels of circulating IL15. In relation to muscle mass, IL-15 has been shown to cause
skeletal fiber growth and stimulate myogenic differentiation (5,6). IL-15 has also been
shown to have a profound effect on the immune system, stimulating NK cell cytotoxicity,
increasing immunosurveillance and protecting from tumor development (7). Therefore,
our central hypothesis is that overexpression of IL-15 will preserve muscle function,
along with increasing the immuneosurveillance of T cells and NK cells, there by
attenuating cancer cachexia and the subsequent severe tumor progression. Currently,
we have bred an IL15 skeletal muscle overexpressor mouse that we will inject with the
EO771 adenocarcinoma cell line in order to examine the effects of IL15 overexpression
on cancer cachexia. We used these mice in conjunction with our background in muscle
testing to address our hypothesis by completing the following aims.

Aim 1: Determine the effects of IL15 skeletal muscle overexpression on muscle
weight and muscle dysfunction seen in cancer cachexia.
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Our working hypothesis is that IL 15 overexpression will preserve muscle function in the
presence of cancer cachexia. From our preliminary data, we know the EO771 breast
cancer cell line causes increased muscle dysfunction along with significant muscle
wasting. We expect to see a preservation of muscle force and a resistance in fatigue in
the presence of IL15 overexpression in tumor bearing mice.

Aim 2: Determine the effects of IL15 skeletal muscle overexpression on cell
populations in the spleen and infiltrating spleen cells in the solid tumor.
Our working hypothesis is that IL15 overexpression will stimulate an increase
percentage of Cytotoxic and Helper T cells and NK cells in both the spleen and tumor of
the transgenic mouse. Due to the ability of these cells to combat tumor formation and
metastasis, we believe IL15 overexpression will reduce severity of tumor progression
and symptoms experienced during cancer cachexia.
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Chapter 2.
Background:
2.1
Cancer Cachexia

Cancer is responsible for nearly 1,500 deaths every day, with fifty percent of
these patients experiencing cachexia (8). Cachexia is generalized as a weakness and
wasting induced by a severe chronic illness.

The effects of cachexia are often

exacerbated by the disease itself creating a self-sustaining loop. One key component of
cancer cachexia is the extreme depletion of skeletal muscle mass compounded with
profound fat loss, along with severe fatigue in patients (2). The main contributors to this
disease are believed to be abnormal fluctuations in cytokines, hormones and tumor
derived factors that alter the cellular environment (9). Cancer cachexia is not limited to
skeletal muscle alterations, this disease is also associated with neuroendocrine
disorder, systemic inflammation, fat atrophy, and overall metabolic dysfunction (10).
Current treatment for cancer cachexia is multimodal in nature.

The basics

include nutritional intervention along with supplemented exercise in order to stave off
the wasting effects(11,12). While these treatments do little to reverse the effects of
cancer cachexia, they can potentially reduce the symptomology in some cases (13).
The

significant

problem

with

traditional

treatment

methods

for

cancer

(i.e.

chemotherapy, radiotherapy) is the exacerbation of cachexia, further decreasing the
prognosis of survival after treatment (14).

Recent drug trials in rats revealed a

potential combination therapy that could alleviate the cachectic effects of cancer all
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while reducing tumor burden (15). The problem with this treatment is that these drugs
could have severe adverse effects in human subjects.

Thus, it becomes critical to

discover treatment options that attenuate these adverse reactions allowing other
primary treatment to reduce tumor burden and move the cancer into remission.

2.2
Biomarkers and Indicators of Cancer Cachexia

Markers of inflammation, skeletal muscle degradation markers and tumor derived
compounds all show some degree of significance in regards to cancer cachexia and
subsequent pathways of fatigue (16). The main biomarkers we are concerned with in
this instance are; Atrogin-1, Murf-1, TNFα, IL-6, IL-15 and IL-15rα. TNFα has long been
considered one of the more prominent indicators of cancer cachexia.

This

proinflammatory

and

cytokine

is

believed

to

play

a

role

in

growth

angiogenesis/metastasis of cancer cells (17). More importantly high levels of TNFα
have been linked with remodeling of stromal development along with being an
endogenous tumor promoter (18).

There is evidence that suggests the pro-

inflammatory cytokine IL-6 also plays an important role in cancer cachexia (19). While a
main indicator of cachexia, IL-6 is believed to mediate the acute phase response
involved with early infection and inflammation (20).

With progression of disease

however, IL-6 has been shown to increase and inhibit cancer cell apoptosis and create
drug resistance (21).

Atrogin-1 and Murf-1 have both been identified as muscle-

specific E3 ubiquitin ligases that are transcriptionally increased in the presence of
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atrophy/atrophy-induced conditions (22).

These markers are enriched in skeletal

muscle making them excellent markers of muscle atrophy in relation to cancer cachexia.
IL-15, as previously mentioned, promotes mitochondrial biogenesis and fatigue resistant
properties. Along with this, IL-15 has a highly specific binding partner IL-15rα. When
bound together, they have the ability to act directly on skeletal muscle in a pro-oxidative
manner (23). Decreases in these two markers could possibly be a mechanistic link
between the increases in fatigue found in cancer cachexia with the decrease in
mitochondrial biogenesis.
Importantly, cancer cachexia can be identified by decreases in bodyweight
associated with severe loss of adipose tissue and muscle mass (9).

Measuring

bodyweight is an easy and noninvasive way to gauge progression. Measuring cross
sectional area of a muscle section however, can provide a more comprehensive
measurement of muscle wasting. Indeed, cancer cachexia has been found to decrease
cross sectional area with progression of disease, yielding more fibers that are smaller in
size (24,25). This can yield a muscle that fails to generate maximal amounts of force
like their non-cachectic counterparts.

2.3
Immune Function during Cancer Cachexia

Natural Killer (NK) cells express the ability to target specific cells without the
need for antibody recognition (26). In higher concentrations NK cells can identify and
kill foreign pathogens increasing the productivity of the immune system (27). Another
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key component in immune function is the Helper and Cytotoxic T Cells. Specifically,
Helper T cells (CD4+) play a central role in regulating nearly all antigen-specific immune
responses to invading pathogens (cancer cells)(28). Just as important are the Cytotoxic
T cells (CD8+), being able to induce tumor cell death upon direct recognition of peptide
antigens (29).

Stemming from the alterations in skeletal muscle comes further

dysfunction in the way of the immune response to cancer cachexia. The alterations
associated with cancer cachexia mostly affect innate responses to pathogens both in
the tumor and systemically (30). A large issue with many cancers is the ability of the
cells themselves so shed antigens or even promote T cell and NK cell lysis (31).
Another mechanism blunting immune response is the tumors microenvironment
preventing expansion/proliferation of helper and cytotoxic T cells, all while increasing
the pro-inflammatory response causing eventual suppression of these cell types (32).
The problem with treating cancer with one specific drug is that it can alter a
patient’s physiological homeostasis. Complications can arise with drugs that target the
cancer cells or specific symptoms of cancer cachexia (anorexia) (33). One major
adverse effect is immune suppression, which further inhibits the body’s response to
invading pathogens increasing morbidity (34). The inflammation response to cancer
cachexia mainly involves the previously mentioned pro-inflammatory cytokines IL-6 and
TNFα. TNFα has been shown to promote adhesion of free floating tumor cells along
with promoting malignancy (35,36). IL-6 shows similarities, promoting both cancer cell
growth, along with resistance to therapy (37).

With these alterations to immune

function, along with the increase in fatigue from cancer cachexia, an ideal treatment is
needed that can alleviate these symptoms without exacerbating the cancer itself.
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2.4
IL-15s Role in Cancer Cachexia

The primary goal of this research is to ascertain the ability of IL-15 to attenuate
muscle fatigue and maintain immune function during progression of cancer.

If

confirmed IL-15 therapy would complement other treatments in the reduction of cancer,
increasing longevity and survival rates among patients. IL-15 is a recently discovered
four-helix bundle cytokine (38). Skeletal muscle is considered to have the largest pool
of IL-15 mRNA, with increases in systemic IL-15 exhibiting a pro-oxidative environment
(39,40). Therefore, we proposed the use of an IL-15 overexpressor mouse in order to
test the effects of IL-15 during a cachectic state.

IL-15 has been shown to promote a

pro-oxidative phenotype in skeletal muscle creating fatigue resistance along with
increasing markers for mitochondrial biogenesis (41). With the increased mitochondria
biogenesis, muscle fatigue would be reduced. This proposed shift in mitochondria
volume could potentially alleviate any fatigue induced by cancer cachexia.
Il-15 is believed to promote maturation in NK cells and T cells, allowing for an
increased immune response in association with invading pathogens (42).

Along with

this, IL-15 would promote greater immunesurveillance and encourage infiltration of the
primary tumor, reducing overall tumor burden (42-44). Understanding how IL-15
overexpression effects cancer cachexia in a mouse model is the first step in identifying
its effectiveness as a supplemental therapy. We expect that our research will identify IL15 as a mitigator of cancer cachexia, reducing overall severity and associated
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symptomology. Upon the conclusion of the proposed study, we will have a feasible idea
of the next steps needed in order to apply this to a clinical environment.

2.5
Background summary, aims, and hypothesis

The symptomology of cancer cachexia brings about multiple complications that
can lead to early morbidity. The primary goal of this research is to solidify a treatment
method which attenuates cachexia. Once established, we will than look into clinical
dosing aspects and potential combination therapy to than reduce tumor burden and
more importantly reduce the rate of muscle fatigue. We expect that our research will
identify IL-15 as a mitigator of cancer cachexia, reducing rate of muscle fatigue and
increasing the immune response to the tumor. With increasing circulating levels of IL15 comes an increase in biomarkers of mitochondrial biogenesis (i.e. PGC-1α,
PPARα/δ).

Through transcriptional activation and increased signaling comes a

subsequent increase in the amount of mitochondria per cross sectional-area.

This

creates a more oxidative fiber type in skeletal muscle, promoting a fatigue resistant
phenotype. IL-15 is already well-published in promoting immunosurveillance through
proliferative effects on NK cells and cytotoxic CD8 T cells.
With this in mind this project has two specific aims: first, determine the effects of
IL-15 overexpression on reducing the rate of muscle fatigue, and second, to determine
the effects of IL-15 overexpression on NK cell and T cell populations in the spleen and
tumor of injected mice.

For these two aims, we injected IL-15 skeletal muscle
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overepressor mice and litter controls with the EO771 adenocarcinoma cell line. The
EO771 cell line is ER-positive and immunosuppressive in nature.
tissues and muscle were collected and analyzed.

After 4 weeks all

It was hypothesized that IL-15

skeletal muscle overexpression would attenuate the increased rate of muscle fatigue
experienced in cachectic tumor burdened mice when compared to littermate controls.
Furthermore, it was hypothesized that IL-15 skeletal muscle overexpression would
increase NK cell and T cell count in the spleen and tumor when compared to littermate
controls.
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Chapter 3

The EO771 Adenocarcinoma Breast Cancer Cell Induces Cancer Cachexia at 4
Weeks in C57BL/6WT Mice.

Joseph F. Bohlen1, Sarah A. McLaughlin3, Sijin Wen4, Emidio E. Pistilli1,2

1 West Virginia University School of Medicine, Division of Exercise Physiology; 2 Center
for Cardiovascular and Respiratory Sciences; 3 Mary Babb Randolph Cancer Center; 4
Department of Biostatistics
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The EO771 Adenocarcinoma Breast Cancer Cell Induces Cancer Cachexia at 4
Weeks in C57BL/6WT Mice.

Severe muscle wasting and muscle dysfunction (cachexia) are considered incurable
complications associated with a wide variety of chronic diseases. Cachexia significantly
decreases the quality of life for cancer patients; more specifically, it leads to an overall
poor prognosis for recovery and accounts for ~40-50% of cancer patient morbidity.
Cachexia is classified by a severe loss of body weight due to a complete loss of fat and,
more pertinent to this study, profound loss of skeletal muscle mass. Breast cancer is
considered the most frequently diagnosed cancer in females accounting for 14% of
cancer deaths with ~27% of these patients experiencing cachexia. Therefore, we
hypothesize that mice with severe cancer cachexia following 4 week cell injection
(EO771) will show decreases in force production along with decreased fatigue
resistance. PURPOSE: To determine whether the EO771 cell line induces a solid
tumor and subsequently causes cancer cachexia altering muscle weight and function.
METHODS: C57BL/6WT female mice were split into three groups consisting of an uninjected control group (n=8), a 2 week post injection group (n=5) and a 4 week nonulcerated tumor (n=4) and ulcerated tumor post injection group (n=6). Isometric force
and fatigue properties were determined in EDL and soleus muscles ex vivo while all
other muscles and organs were dissected and weighted. RNA was isolated from tibialis
anterior muscles and reverse transcribed for semi quantitative PCR. DNA was isolated
in order to look at mitochondrial DNA content using RT-PCR. RESULTS: 4WK
ulcerated EDL muscles showed a significant decrease in tetanus force (CON 214.0 ±
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23.26 nM vs. 4WK ulcerated 149.9 ± 42.58 nM, p<0.0001) with a shift in the force
frequency curve, along with significant loss of muscle mass compared to both the CON
and 2WK time point(CON 10.58 ± 1.152 mg vs. 4WK ulcerated 7.325 ± 0.9621mg,
p<0.0001). 4WK mice also showed increases in markers for inflammation and muscle
atrophy CONCLUSION: The results of this study suggest that the EO771 cell line does
in fact induce cachexia. The decrease in muscle weight, along with an increase in
fatigue coincides with the symptomology of cancer cachexia. Furthermore, the
increases in inflammatory markers, atrophy markers highlight the physiological
alterations taking place in this disease. Methods of therapy can now be applied to this
particular cell line when considering attenuation of cancer cachexia.
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INTRODUCTION
Severe muscle wasting (cachexia) is considered an incurable complication
associated with a wide variety of chronic diseases. Cachexia significantly decreases
the quality of life for cancer patients; more specifically, it leads to an overall poor
prognosis for recovery and accounts for ~40-50% of cancer patient morbidity(1).
Cachexia is classified by a severe loss of body weight due to a complete loss of fat and,
more pertinent to this study, profound loss of skeletal muscle mass.

The

symptomology of this disease includes fatigue, anorexia and abnormal biochemistry, in
turn altering several metabolic pathways in tissues and organs.

(2,3) Generalized

circulating factors such as tumor derived compounds, inflammatory cytokines, acute
phase proteins and skeletal muscle degradation markers all play significant roles
respectively. (3) Specifically, TNF α and IL – 6 have been documented to increase
progressively along with the severity of cancer (4). Markers of acute muscle atrophy
such as, MAFbx/Atrogin-1 and Murf1 have also shown upregulation in multiple models
of cancer (5). The downstream effect of these factors is usually a loss of myofibrillar
proteins in muscle cells resulting in muscle weakness and fatigue. This is exacerbated
by the increase in apoptosis compounded with impaired regeneration capabilities seen
in cancer patients(6).

Interestingly cachexia has shown selective atrophy in fast

glycolytic fibers, associated with increases in proinflammatory cytokines (7).
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One possible mechanism behind the cachectic fatigue resides in alterations in
mitochondrial function. Considered multi-functional organelles, mitochondria provide a
majority of the ATP in cells along with participating in a plethora of signaling cascades,
including apoptosis.

In a Lewis Lung Carcinoma model, mitochondrial ATP synthesis

was shown to decrease suggesting mitochondrial dysfunction as the potential cause for
muscular fatigue (8). Circulating factors produced by cancer cells have also shown to
alter electron transport chain

(ETC) activity, reduce basal respiration, along with

potentially creating a self-amplifying loop of oxidative stress (9).One implication behind
this is the upregulation of reactive oxygen species (ROS), signaling the induction of
tumorigenesis and metastasis (10).

UCP3, the predominant uncoupling protein in

skeletal muscle, has also shown marked alterations.

Increases in amount and activity

of UCP3 show reductions in proton gradient across the inner mitochondrial membrane.
This increases energy expenditure via the dissipation of energy as heat (11).
Breast cancer is considered the most frequently diagnosed cancer in females
accounting for 14% of cancer deaths (12). Traditional interventions do little to attenuate
the progressive wasting associated with cancer cachexia. There is a general decrease
in food intake, compounded with a state of hypermetabolsim that yields standard
nutritional approaches futile (13).

Therefore, it becomes pertinent to identify ideal

mouse models of cachexia in order to test feasible methods of treatment that do not
exacerbate these wasting symptoms.

In this study we examined the effect of the

EO771 breast cancer cell line on initiation of muscle wasting and dysfunction in
C57BL/6 WT mice.

The EO771 breast cancer cell line is aggressive and proliferates

rapidly. In this case we wanted to show solid tumor development in immunocompetent
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mice looking at metastases, muscle wasting/dysfunction, tumor burden and metabolic
alterations following 2 and 4-week tumor bearing periods. We hypothesize that mice
with severe cancer cachexia will show decreases in force production along with
decreased fatigue resistance. Concluding this study, we plan to identify this as an ideal
model for use when studying breast cancer cachexia looking for potential therapies to
attenuate the downstream alterations.
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METHODS
Mice
C57BL6WT mice were purchased from The Jackson Laboratory (n=23) and randomly
assigned to a control group (Control; n=8), mice that were euthanized following 2 weeks
of tumor growth (2WK, n=5), and mice that were euthanized following 4 weeks of tumor
growth (4WK, n=10).

The 4WK group was subsequently divided into mice that

developed an ulcerated tumor (4WK-UT; n=6) and mice that developed a non-ulcerated
tumor (4WK-NUT; n=4). Mice were housed in the animal vivarium at West Virginia
University at 22°C under a 12:12-h light-dark cycle and received food and water ab
libitum. All animal experiments were approved by the Institutional Animal Care and Use
Committee at West Virginia University.

E0771 Murine Breast Cancer Cells
The E0771 cell line used in these studies was kindly provided by Dr. Metheny-Barlow
from Wake Forest University. E0771 cells were cultured using aseptic technique and
maintained under standard mammalian culture conditions (37ºC, 99% humidity, 5%
CO2). Cells were maintained in high glucose DMEM supplemented with 10% FBS to
maintain active proliferation.

Cells were passed via trypsinization using 0.25%

trypsin/EDTA in Hanks buffered saline solution (Gibco).

Cells were grown until ~90%

confluent at which time they were prepped for injection. Cells were trypsinized and
resuspended in sterile PBS.

A cell count was performed yielding 1 million cells per

100µL injection into the 4th nipple (mammary fat pad) of female C57BL/6 WT mice.
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In vivo tumor bioluminescence and volume measurements.
Mice were injected with luciferase-expressing EO771 breast cancer cells and imaged
weekly for quantitative evaluation of tumor growth and dissemination. About 150 mg/kg
D-luciferin (Caliper Life Sciences) was injected into the peritoneum.

Images were

obtained using the IVIS Lumina-II Imaging System and Living Image-4.0 software (14).

Ex vivo muscle physiological analysis
Muscle contractile properties were examined in the fast extensor digitorum longus
(EDL) and slow soleus muscles of experimental mice. Mice were deeply anesthetized
by breathing 4% isoflurane delivered through a nose cone at a flow rate of 1 l/min.
Muscles were removed with both proximal and distal tendons intact, and nylon sutures
were attached to the tendons. Muscles were transferred to an oxygenated tissue bath
that contained Ringer solution (100 mM NaCl, 4.7 mM KCl, 3.4 mM CaCl2, 1.2 mM
KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, and 5.5 mM D-glucose) maintained at 22°C.
Ex vivo muscle stimulation was performed using a commercially available muscle
physiology system (Aurora Scientific, Ontario, CA). Muscle length was adjusted to
obtain the maximal twitch response (i.e., Lo). Three twitch contractions were performed
all separated by 2 min. Parameters analyzed from isometric contractions included peak
isometric twitch force (Pt), time to peak twitch tension (TPT), half-relaxation time of
twitch contraction (½ RT), and peak isometric tetanic force (Po).

Isometric tetanic

contractions were stimulated in muscles at a stimulation frequency of 120 Hz for EDL
muscles and 80 Hz for soleus muscles, a stimulation current of 20 V, and lasting 500
ms. Following isometric contractions, the muscles remained in oxygenated Ringer’s for
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5 minutes prior to the repeated-stimulation fatigue protocol. Muscle fatigue was
analyzed using a repeated stimulation protocol lasting 6 min and consisting of repeated
40-Hz tetanic trains that occurred once every second and lasted 330 ms. The fatigue
index was calculated as the difference in force from the first contraction and every tenth
subsequent contraction, and plotted as a fatigue curve. (Burke1973, Pistilli 2011)
Muscles were flash frozen in isopentane cooled to the temperature of liquid nitrogen
and stored at –80°C. Muscle CSA was calculated by dividing the muscle mass by the
product of the muscle density coefficient (1.06 g • cm3), muscle Lo, and the fiber length
coefficient (EDL: 0.45, soleus: 0.69). This whole muscle CSA value was used to
calculate specific force (i.e., absolute force mN • muscle CSA–1) (Brooks 1988, Lynch
2001)

Muscle Histology and Morphology
Serial frozen sections (10 μm thick) of EDL and SOL muscles were obtained using a
cryostat at −21°C and placed onto glass slides (Superfrost/Plus, Fisher Scientific).
Sections were stained with Alexa Flour® 488-conjugate AffiniPure Goat Anti-Rabbit IgG
(Jackson ImmunoResearch Labratories, INC) and ANTI-LAMININ Affinity Isolated
Antigen Specific Antibody(SIGMA-ALDRICH®) and then mounted with 4’,6-diamidino-2phenylindole (DAPI) mounting medium (Vector Laboratories, Burlingham, CA).

Mitochondrial DNA content
Total DNA (genomic and mitochondrial) was extracted from tibialis anterior (TA)
muscles from female mice using a DNeasy Blood and Tissue kit (Qiagen, Valencia, CA)
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and quantified using a Nano-Drop spectrophotometer (ThermoScientific, Waltham, MA).
TaqMan primers for mitochondrial DNA-encoded cytochrome-c oxidase subunit II
(COXII) and nuclear-encoded 18S ribosomal RNA were used to perform real-time
qPCR. The wells of a 96-well optical reaction plate were loaded with a 20-μl volume
consisting of TaqMan 10X PCR Master Mix, a primer mix for either the mitochondrialencoded gene or the nuclear-encoded gene, and DNA diluted to a concentration of 5
ng/μl. Each DNA sample was analyzed in pairs and amplified in an Applied Biosystems
7900HT Fast Real-Time PCR system. The cycle threshold (CT) values of the
mitochondrial-encoded COXII gene and the nuclear-encoded 18S gene in muscles
C57BL/6 WT mice were used to quantify the fold change using the ΔΔCT calculation
(Livak 2001).

mRNA Analysis
Total RNA was isolated using Trizol reagent (Life Technologies, Grand Island, NY), as
previously described (15). RNA quantity and quality were assessed using a Nano-Drop
2000 spectrophotometer (ThermoScientific, Waltham, MA); the 260/280 ratio for all
samples used was between 1.8 and 2.1. Two micrograms of total RNA was reverse
transcribed to make cDNA using a high-capacity reverse transcription kit according to
manufacturer's instructions (Life Technologies, Grand Island, NY). Amplification was
performed in a reaction consisting of 8.5 μl nuclease-free H2O, 12.5 μl 2X Taq-Pro Red
Complete 1.5 mM MgCl2 master mix (Denville Scientific, Metuchen, NJ), 1.0 μl forward
primer, 1.0 μl reverse primer, and 2 μl of DNA template to make a 25 μl total reaction
volume. Primers were constructed from published sequences.

Primer pairs for IL-15,
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IL-15 rα, IL-6, TNFα, Murf1 and Atrogin-1 were coamplified with primer pairs for 18S
(Ambion, Austin, TX). The number of PCR cycles was determined in preliminary
experiments to ensure analyses were done in the linear range of amplification.
Following amplification, each reaction was visualized following gel electrophoresis in 1%
(wt/vol) agarose gels stained with ethidium bromide. PCR bands were quantified using
the ImageJ software program (http://rsbweb.nih.gov/ij/). Signals for the gene of interest
were normalized to the bands for 18S that were amplified in the same reaction.
Spleen Cell Isolation
Spleens were dissected from mice and spleen cell populations were isolated by creating
a cell suspension in 1.5% FBS RPMI. Cells were then passed through a 70µm filter into
a new tube. Red blood cells were lysed by adding 4 mL of fresh Tris-NH4Cl at room
temperature and letting stand for 3 minutes. Tris- NH4Cl was inhibited with 5 mL of 10%
FBS RPMI and two washing steps performed using 1.5% FBS RPMI. A cell count was
performed yielding 1 million cells per vial. Samples were than stored in 0.5%
paraformaldehyde until being re-suspended in FACS buffer for flow cytometry analysis.
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RESULTS
In vivo tumor burden. One million E0771 tumor cells were implanted into the
mammary fat pads of female wild type C57BL/6 mice and cell bioluminescence and
tumor volume were monitored weekly. As seen in Figure 1A, representative images
display a progressive increase in cell bioluminescence and tumor size through four
weeks.

E0771 tumor induced alterations in body and muscle mass. The body mass of
female C57BL6 following 2 weeks of tumor growth was not significantly different from
control non-tumor bearing mice. However, the body mass of mice following 4 weeks of
tumor growth was 28% less than both control and 2 week mice. The masses of
individual skeletal muscles of the lower limb all displayed a similar response pattern.
The normalized muscle masses of muscles from female C57BL6 mice following 2
weeks of tumor growth was not significantly different from control non-tumor bearing
mice (Figure 8). The normalized muscle masses in mice following 4 weeks of tumor
growth were significantly less than control mice and mice following 2 weeks of tumor
growth (Figure 8). The absolute and normalized mass of the spleen was greater in
mice following 4 weeks of tumor growth compared to control mice and mice following 2
weeks of tumor growth. (Figure 8E)

Fatigue properties. Muscle fatigue was analyzed using a repeated stimulation
protocol, with the fatigue index calculated as the percent difference of each contraction
from the initial contraction of the protocol. When the fatigue index was plotted, a clear
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pattern emerged with respect to the duration of tumor exposure. The fatigue index
curve of EDL muscles from mice exposed to 4 weeks of tumor growth was shifted to the
left during the initial 20-70s of the protocol compared to the fatigue index of EDL
muscles from control mice and mice exposed to 2 weeks of tumor growth, indicating a
significant loss of force with repeated contractions during this timeframe. There were no
differences in the fatigue index curve of EDL muscles from control mice compared to
mice exposed to 2 weeks of tumor growth (Figure 4A). The total area under the curve
(AUC) was calculated for each fatigue curve. Supporting the fatigue curves, there was
a significantly lower AUC when comparing the fatigue curves of EDL muscles from mice
exposed to 4 weeks of tumor growth to control mice. In the soleus muscle, there were
no significant differences between the groups in the fatigue index (Figure 4B) or the
AUC. The mtDNA content, as assessed by qPCR, showed a statistical significance for
a reduction in muscles from mice exposed to 4 weeks of tumor growth compared to
muscles from control mice, suggesting the duration of tumor growth affected
mitochondrial density in skeletal muscles (Figure 4C).

Isometric force production. The CT of EDL muscles was significantly longer in mice
following 4 weeks of tumor growth compared to control mice (Figure 2C). The 1/2RT of
EDL muscles was also longer in mice following 4 weeks of tumor growth compared to
control mice (Figure 2D). Absolute maximal tetanus force of EDL muscles was
significantly lower in mice following 4 weeks of tumor growth in the ulcerated group
compared to control, 2WK and 4WK non-ulcerated mice (Figure 3C). Absolute tetanus
force was also significantly lesser in EDL muscles from 4 week ulcerated tumor mice at
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stimulation frequencies of 80, 100, 120, and 150Hz (Figure 3A). When the forcefrequency relationship was expressed as force normalized to maximal force, there was
a significant leftward shift of the relationship, such that force was significantly different in
4 week mice at stimulation frequencies of 1, 5, 10, and 25Hz (Figure 3B).
There were no differences in the CT or 1/2RT of twitch contractions in SOL
muscles (Figures 2G, H). Absolute maximal tetanus force was significantly lower in
4WK mice compared to control and 2 week mice (Figure 3F). Absolute tetanus force
was also significantly lesser in SOL muscles from 4WK mice at stimulation frequencies
of 50, 80, and 100Hz (Figure 3D). There were no differences in the force-frequency
relationship when expressed as force normalized to maximal force (Figure 4F).

Single Fiber Area Analyzing cross sectional area (CSA) following laminin staining we
saw a significant shift in the 2WK and both 4WK groups to the left in the EDL muscles,
indicating a greater percentage of smaller fibers in these muscles in response to cancer.
(Figure 6 A, B) No shift was seen on the SOL muscles for any groups (Figure 6 C, D)

mRNA Expression Control mice showed the highest levels of IL-15 and IL15rα. In
regards to IL-15 there was a linear decrease in skeletal muscle expression, with the 4
week groups expressing the lowest amount (Figure 5C). IL-15 rα showed a significant
decrease in 2week and both 4 week groups when compared to control mice (Figure
5F). IL-6 expression increased linearly with progression of cancer, with the 4 week
ulcerated group having significantly high levels (Figure 5 B). While TNF α did show
marked increase, levels in the 4 week ulcerated group did not reach significance(Figure
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5 E). Atrogin 1and Murf 1 showed a significant increase in the 4 week ulcerated group
when compared to all other groups (Figure 5 A, B).
IVIS Imaging Tumor progression increased linearly from week to week. These data
were confirmed with caliper measurements (0.5236 x W 2 x L) looking at the volume of
the tumor (Figure 7B). The photon flux from the tumor is proportional to the number of
light emitting cells and the signal can be measured to monitor tumor growth and
development (Lim 2009) (Figure 7C). Flux numbers began an exponential increase at
the 3 and 4WK time points verifying the increase in tumor growth. At the 4WK time
point there was a contrast between large solid tumors and smaller necrotic tumors
containing ulcerations (Figure 7 A, B). These data indicate a differentiation in response
to the Eo771 cell line.

Spleen Cell Percent No significant differences were seen between T cell or NK cell
populations (Figure 9 A, B). A t-test between the CON and 2WK groups revealed a
significant decrease in T cell % at the 2WK time point.
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DISCUSSION
The profound muscle wasting from cancer cachexia is associated with muscle
weakness and reduced strength (16). Many attribute muscle wasting as the main
contributor to the decrease in strength and muscle weakness, some studies suggest
additional factors that contribute to the alterations in excitation-contraction coupling and
development of force (17). Inflammatory cytokines secreted by and in response to
tumors have been shown to directly induce signaling pathways that have been shown to
upregulate enzymes that induce skeletal muscle protein turnover (18). Specifically, in
this model there is a significant increase in IL-6 in the 4WK Ulcerated group, one of the
main inflammatory markers in cancer cachexia. While there was no significant
difference in TNF α in skeletal muscle, there was a greater increase in the 4WK
Ulcerated group. These data indicate the 4WK Ulcerated group having a more severe
response to the cancer and a subsequent increase in cachexia. Significant increases in
Atrogin1 and Murf1 along with decreases in fiber area and single fiber CSA in all cancer
groups in the EDL muscle coincide with muscle atrophy seen in cancer cachexia. While
not entirely similar to muscular dystrophy loss of dystrophin protein is associated with
increases in MuRF1/Atrogin1activity increasing myofibrillar protein breakdown (19).
Furthermore, muscle weights for the Gastrocnemius, Tibialus Anterior, Quadriceps,
Plantaris, EDL and SOL showed significant decrease in the 4-week time point, even
when normalized to overall body mass, indicating this cancer cell line having a
cachectic effect on muscle mass. Indeed, mice in the 4WK Ulcerated group
experienced severe cachexia illustrated by weight loss measured after tumor removal.
EDL muscles showed increased CT and 1/2RT indicating alterations in calcium handling
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with the contractile machinery, further contributing to muscle dysfunction. EDL force
frequency expressed as force normalized to maximal forces expressed a significant
leftward shift in both 4WK groups indicating these muscles are producing lower force.
Furthermore, the EDL of 4WK mice had a significant drop in force from 30-70
contractions during the fatigue protocol indicating a significant increase in fatigue in
these mice. This shift further exemplifies the contractility alterations seen in many
cancer cell lines that exhibit a cachectic/dysfunctional effect (17).

Il- 15rα has been

implicated as being a binding partner for IL-15, increasing biological activity and half-life
of IL-15 (20). In our model we show significant decreases in IL-15 and IL-15rα mRNA
levels in all cancer groups. Furthermore, decreases in IL-15 and IL-15rα can be
associated with a decreased rate of mitochondrial biogenesis contributing to the
increase in fatigue seen in the EDL muscles at 4WK time point. This decrease yields
potentially less functional mitochondria decreasing the overall oxidative capacity of the
muscle (8, 9, 10). Indeed, the mtDNA assay showed significant decreases in genomic
DNA in both 4WK time points coinciding with our fatigue data. While SOL muscles did
experience a decrease in max tetanic force at both 4WK time points and a significant
decrease in weight at the 4WK Ulcerated time point, all other physiological parameters
were unchanged. This is supported by previous work showing preservation in a more
oxidative muscle in cancer cachexia (7). Spleen cell data showed do differences
between groups in T cell% or NK cell%. This perhaps could be due to a small sample
size or the immunosuppressive nature of this cell line at later stages of development
(21).
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These data highlight a clear separation in progression and severity of cancer
cachexia. There was a clear delineation at the 4WK time point leading to two different
phenotypic responses to the E0771 cell line which can be representative of ~40-50% of
cancer patients (1). Our 4WK Ulcerated mice showed significant increases in
transcriptional markers of inflammation, atrophy along with a significant decrease in
tetanic force combined with an increased rate of fatigue associated with a decrease in
mtDNA content. While our 4WK Non-Ulcerated group did exhibit similarities in fatigue
and mtDNA content, we saw no significant differences in our markers for atrophy and
inflammation along with no differences in maximal tetanic force. In conclusion we
establish that the EO771 adenocarcinoma cell line produces a solid tumor increasing in
size with progression of disease. At the 4WK time point mice exhibited signs and
symptoms of cancer cachexia supported by the decrease in force output, increased rate
of muscle fatigue and decrease in muscle mass. These data indicate the EO771 cell
line is ideal for use in determining the effects of certain therapies on cancer cachexia.
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Figure 2
2

EDL and SOL WT, CSA, CT and ½ RT: A, B. EDL weight (mg) and CSA (mm ) showed significant decreases in the 4
WK Ulcerated Tumor group. E, F. EDL CT and ½ RT showed significant increases hinting at alterations in Calcium
handling during contractions. C, D. SOL weight (mg) and CSA (mm2) showed significant decreases in the 4 WK
Ulcerated Tumor group. G, F. No differences were seen in SOL CT and ½ RT. CON (n=8), 2WK (n=5), 4WK Non
(n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 3
EDL and SOL Force Frequency and Tetanus. A, B. EDL Absolute and Relative Force Frequency showed a shift similar to
a oxidative muscle phenotype in both 4WK groups indicating a decrease in absolute force output and force output
relative to maximal contraction showing EDL muscle producing higher forces at earlier stimulation frequencies. E.
4WK Ulcerated Tumor EDL Max Tetanus showed a significant decrease in force (mN) when compared to other groups.
C, D. Both 4WK groups showed a shift in the Absolute Force Frequency however, Relative Force Frequency showed no
differences. F. SOL Max Tetanus showed a significant decrease in both 4WK tumor groups. CON (n=8), 2WK (n=5),
4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 4
EDL and SOL Fatigue curve, Mitochondria DNA Content. A. Both 4WK Tumor bearing groups showed a significant
increase in fatigue shifting down and to the left. 2WK mice remain un-affected when compared to CON B. No
Differences were found in SOL Fatigue across all groups. C. Mitochondrial DNA Content showed a significant
reduction in content in both 4WK groups, coinciding with the shift in the fatigue curve in A. CON (n=8), 2WK (n=5),
4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 5
RNA Isolation from Tibialus Anterior muscles: All groups represented as Con/2WK/4WK NUT/4WK UT A. PCR
amplification of Atrogin1 revealed significantly higher levels in the 4WK UT group compared to CON. B. PCR
amplification of IL-6 revealed significantly higher levels in the 4WK UT group compared to CON C. PCR amplification
of IL-15 showed significant decreases in both 4WK groups when compared to CON and 2WK groups. D. PCR
amplification of Murf1 showed significant increase in the 4WK UT group when compared to CON. E. PCR amplification
of TNF-α showed a modest trend towards increasing in the 4WK UT group, however significance was not reached. F.
PCR amplification of IL-15 rα showed significant decreases in all 3 tumor bearing groups when compared to CON. CON
(n=8), 2WK (n=5), 4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 6
EDL and SOL Muscle Fiber Area: A. From Left to Right CON, 2WK, 4WK Non-Ulcerated, 4WK Ulcerated. B. EDL Muscles
show a shift in the Fiber Number with progression of cancer, with a larger culmination of smaller fibers in the 4WK
Ulcerated group. C. The EDL Cumulative Frequency shows a shift to the right indicating similar results as B., D. From Left
to Right CON, 2WK, 4WK Non-Ulcerated, 4WK Ulcerated. E, F. Fiber number and Cumulative Frequency show no real
differences between groups. CON (n=4), 2WK (n=4), 4WK Non (n=4), 4WK Ulcerated (n=4)
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Figure 7
Tumor Weight/Volume and Body Weight: A Tumor Weight of the 3 tumor bearing groups (mg). 4WK Non-ulcerated Tumors
3
weight the most and was significantly greater then both 2WK and 4WK Ulcerated. B. Tumor Volume (mm ) in 3 tumor groups.
8
Similar to weight, 4WK Non-ulcerated tumors had the largest volume compared to 2WK and 4WK ulcerated. C Tumor Flux (x10 )
in 3 tumor groups. Both 4WK groups had a similar trend of a larger tumor flux. D. Body mass after removal of the tumor (mg).
4WK Ulcerated Tumor mice had a significant decrease in body mass. E % Difference in Body Mass. 4WK Ulcerated Mice had the
largest difference in body mass when comparing pre-injection of cells and post-dissection CON (n=8), 2WK (n=5), 4WK Non (n=4),
4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 8 Muscle and Spleen Normalized BW: A. Tibialus Anterior weight normalized to body weight. B.
Gastrocnemius weight normalized to body weight. C. Plantaris weight normalized to body weight. D.
Quadriceps muscle normalized to body weight. E. Spleen weight normalized to body weight. CON (n=8),
2WK (n=5), 4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 9 Spleen T Cell and NK Cell %: A., B. No differences were seen between groups with regards to T Cell or
NK Cell. C. T Cell comparison of CON and 2WK time points shows a significant decrease at 2 weeks. D. No
differences in CON vs 2WK time points. . CON (n=8), 2WK (n=5), 4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05
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Chapter 4
Results: IL-15 Overexpression in Transgenic Mice
4.1
Effects of IL-15 Skeletal Muscle Overexpression on Muscle WT, CSA, CT and ½RT
In order to test the effects of cancer cachexia on skeletal muscle function we
purchased the IL-15 Skeletal Muscle overexpressor mouse from Jackson Laboratory.
These mice have previously been characterized by Quinn (52). In brief, the HSAIL2SP-IL15 construct uses a Human alpha-skeletal actin promoter region, along with an
IL-2 signal peptide region combine with Murine IL-15 cDNA. This construct yields

Figure 10 EDL/SOL Weight and CSA: A., C. CON EDL/SOL Weights with a significant decrease with the CON
Non-Ulcerated group. B., D. CON EDL/SOL CSA with a significant decrease with the CON Non-Ulcerated
group E., G. TG EDL/SOL Weights showing a significant decrease in both the TG Non-Ulcerated and
Ulcerated groups. F. EDL CSA show a significant decrease in both the TG Non-Ulcerated and Ulcerated
groups. H. No statistical differences were seen between groups for SOL CSA. CON (n=8), CON Non (n=8),
CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001
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significant increases in skeletal muscle IL-15 mRNA and protein content, as well as
increased serum levels of IL-15. (52) Mice were bred yielding both IL-15 skeletal
muscle overexpressors (IL-15 TG) and littermate controls (CON). EO771 cells were
cultured and injected into the fat pad adjacent to the 4th nipple. For comparison
purposes mice were grouped into 6 groups; CON (n=8, un-injected), CON NonUlcerated (n=8, injected), CON Ulcerated (n=2, injected), TG (n=7, un-injected), TG
Non-Ulcerated (n=7, injected) and TG Ulcerated (n=4, injected).
With regards to the CON groups, EDL and SOL weights was shown to

Figure 11 EDL/SOL CT and ½ RT for CON and TG: A. EDL CT showed no differences between groups. B. EDL ½
RT showed significant increases in the CON Non-Ulcerated group. C., D. SOL CT and ½ RT showed not
differences in the CON groups. E., F. EDL muscles showed a significant increase in CT and ½ RT in both the TG
Non-Ulcerated and TG Ulcerated Group. G., H. SOL muscles showed no differences between groups in both CT
and ½ RT. CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05,
**=P<0.005, ***=P<0.0001
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significantly decrease with the CON Non-Ulcerated Tumor group (Figure 10A, 10C).
While the CON Ulcerated groups did not reach significance, it is important to note this
group had 2 mice perhaps showing why significance was not reached in this or any of
the subsequent groups.

CSA for both EDL and SOL showed a significant decrease

with the CON Non-Ulcerated Tumor group (Figure 10B, 10D). The TG group showed a
significant decrease in the EDL and SOL weights in both the TG Non-Ulcerated and

Figure 12 EDL Relative and Absolute Force Frequency: A. EDL Absolute Force frequency shows a significant reduction in tetanus
force in the 50-150Hz stimulation frequency’s for the CON Non-Ulcerated and CON Ulcerated. B. EDL Relative Force Frequency
shows no significant difference between groups. C. EDL Maximal Tetanus was significantly reduced in the CON Non-Ulcerated
group. D. EDL Absolute Force Frequency showed a significant reduction in the 100-150Hz stimulation frequency’s for the TG NonUlcerated and TG Ulcerated groups. E. Relative Force Frequency showed a small shift in the 25-50Hz stimulation frequency’s for
the TG Non-Ulcerated and TG Ulcerated groups. F. No statistical differences were seen for maximal tetanus force for the TG
groups. CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001
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Ulcerated groups (Figure 10E, 10G). EDL CSA was shown to significantly decrease in
the TG Non-Ulcerated and Ulcerated groups (Figure 10F) with no effect on SOL CSA
(Figure 10H). Overall we see a similar trend with muscle weights and CSA to the
preliminary study in B6 mice.
No differences were seen between CON, CON Non-Ulcerated and CON
Ulcerated with regards to EDL CT, SOL CT and SOL ½ RT (Figure 10A, 10C, 10D).

Figure 13 SOL Relative and Absolute Force Frequency: A. Sol Absolute Force Frequency showed a
significant decrease in both the CON Non-Ulcerated and CON Ulcerated group compared to the CON
group at the 25Hz-100Hz stimulation frequency. B. Relative Force Frequency show a significant shift at
the 100Hz stimulation frequency in both the CON Non-Ulcerated and CON Ulcerated groups. C. SOL
Maximal Tetanus force showed a significant decrease in the CON Ulcerated group when compared to the
CON group. D. SOL Absolute Force Frequency showed a significant decrease in both the TG NonUlcerated and TG Ulcerated groups at the 80Hz-100Hz stimulation frequency. E. SOL Relative Force
Frequency a significant shift at the 100Hz stimulation in both the TG Non-Ulcerated and TG Ulcerated
groups. F. SOL Maximal Tetanus Force showed no statistical difference between groups. CON (n=8),
CON Non (n=8), 4WK Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005,
***=P<0.0001
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EDL ½ RT did show a significant increase in the CON Non-Ulcerated groups. In the TG
groups, EDL CT and ½ RT both showed significant increases in the TG Non-Ulcerated
and TG Ulcerated group (Figure 11E, 11F). The SOL muscle showed no differences in
either CT or ½ RT. (Figure 11G, 11H).

3.6
Effects of IL-15 Skeletal Muscle Overexpression on Tetanic Force and Muscle
Fatigue

Figure 14 EDL Fatigue Curve for CON and TG: A. EDL fatigue curve showing a significant shift in both the CON
Non-Ulcerated and CON Ulcerated groups for the 20-80 second time points. B. EDL fatigue tracing of the first
100 seconds. C. EDL fatigue curve shows a significant shift in both the TG Non-Ulcerated and TG Ulcerated
groups for the 40-70 second time points. D. EDL fatigue tracing of the first 100 seconds. CON (n=8), CON Non
(n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001
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EDL absolute force in the control group yielded a significant reduction of force
production in the CON Non-Ulcerated and CON Ulcerated indicating a weaker muscle in
the presence of cancer (Figure 12 A). When looking at relative force however we see
no shifts in the force curve, indicating these forces are producing normal tetanus for
their relative frequency of stimulation (Figure 12 B). EDL tetanus force did see a
significant decrease in the CON Non-Ulcerated group (Figure 12 C). These results may

Figure 15 EDL Area Under the Fatigue Curve A. EDL Total Area Under the Fatigue Curve showed a significant reduction in the
Con Non-Ulcerated group compared to CON. B. No statistical differences were seen between TG groups. CON (n=8), 4WK
Non (n=8), 4WK Ulc (n=2), TG (n=7), TG Non (n=8), 4WK (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 16 SOL Fatigue Curve for CON and TG: A. SOL fatigue curve showing a significant shift in in both the CON and
the CON Ulcerated group compared to the CON Non-Ulcerated group. B. SOL fatigue tracing of the first 100 seconds.
C. SOL fatigue curve showing no statistical differences between groups. D. SOL fatigue tracing of the first 100 seconds.
CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001

change when boosting the CON Ulcerated group. EDL Absolute Tetanus Force in the
TG groups saw a significant reduction in the TG Non-Ulcerated and TG Ulcerated
groups compared to control (Figure 12 D). When looking at relative Tetanus there is a
slight significant shift at the 25-50Hz points for the TG Non-Ulcerate and TG Ulcerated
(Figure 12 E). EDL max tetanus however, shows no significant differences between the
groups of TG mice (Figure 12 F). SOL muscles in the control group yielded a significant
decrease in absolute force frequency in the CON Non-Ulcerated and CON Ulcerated
group when compared to the CON group at the 25Hz-100Hz stimulation frequency
(Figure 13A). Relative force frequency however, showed only a significant shift at the
100Hz stimulation frequency CON Non-Ulcerated group and CON Ulcerated group
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when comparing to the CON group (Figure 13B). Interestingly, the CON Ulcerated
group produced significantly less maximal tetanic force when compared to the CON
group (Figure 13 C). Transgenic SOL muscles showed a significant decrease in
absolute force in both the TG Non-Ulcerated and TG Ulcerated group at the 80Hz100Hz stimulation frequencies (Figure 13 D). Similar to the CON group, TG mice
showed a significant shift in the relative force frequency at the 100Hz stimulation
frequency in both the TG Non-Ulcerated and TG Ulcerated (Figure 13 E). TG SOL
muscles showed no statistical differences in maximal tetanus force between any of the
groups. The EDL fatigue tracing of the CON group showed a significant shift down and
to the left in both the CON Non-Ulcerated and CON Ulcerated (20-80 seconds)
indicating a significant amount of fatigue in these mice (Figure 14 A) similar to the
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tracing seen in the B6 preliminary study (Figure 4 A). EDL fatigue tracing in the TG
group showed a significant shift down and to the left in the TG Non-Ulcerated and TG
Ulcerated groups (40-70 seconds) however it was a smaller shift in fatigue as well as a
smaller duration indicating attenuation of fatigue in the EDL muscle (Figure 14 C). EDL
AUC measurements showed a significant reduction in area in the CON Non-Ulcerated
group compared to the CON group Figure 15. EDL TG AUC showed no differences
between groups. SOL fatigue curves for the CON group show a significant shift down
and to the left in the CON and CON Ulcerated group (Figure 16 A). This trend is not
typical but perhaps came about because of the small number of mice in the CON

Ulcerated group and the very large SD of

the CON Non-Ulcerated group. No

Figure 18 CON and TG Tumor Dissociation: No statistical differences were seen between B6 Tumor and
TG Tumor, however there was an overall trend toward increased CD4 (helper) and CD8 (cytotoxic) T
cells in the TG mice. CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05,
**=P<0.005, ***=P<0.0001
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statistical differences were seen between the TG groups (Figure 16 C).
3.7
IVIS, Ultrasound, Tumor and Spleen cell isolation:
Images were taken every week of both the bioluminescence of each tumor using IVIS
imaging as well as the volume of each tumor measured by In Vevo Ultra sound. These
data showed no statistical differences in progression of tumor growth when comparing
groups. We did see an overall trend towards reduction of tumor size around the 2 week
group, however this did not reach significance. After dissecting out whole tumors from
mice, single cell suspensions were generated and stained looking for differences in T
cell and NK cell populations. No statistical differences were seen between B6 Tumor
(n=3) of TG Tumor (n=5), however there was a trend toward increasing in the TG Tumor
group which could be further vilified if the groups were increased (Figure 18). When
analyzing single cell suspension of the spleen from both CON vs CON Tumor and TG
vs TG Tumor we saw a significant reduction in T Cell % in both groups (Figure 19). We
did not see any other statistical differences in T Cell or NK Cell populations however in
any of the spleen groups. (Figure 19, 20)

3.8
Tumor/Mouse weight, Muscle/BW
No differences were seen between either CON or TG groups with regard to tumor
volume or weight (Figure 21 A and B). Body mass was reduced significantly after
removal of the tumor in both CON Non-Ulcerated and CON Ulcerated groups, however
% change in body mass was not significant (Figure 21 C and D.)
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TG Non-Ulcerated mice showed a significant reduction in body mass once the tumor
was removed compared to TG uninjected (Figure 21 G). TA/BW showed a significant
decrease in both the CON Non-Ulcerated and CON Ulcerated muscles when compared
to CON muscles (Figure 22 A). Both the Gastroc/BW and Quad/BW showed significant
decreases in the CON Non-Ulcerated when compared to CON muscles (Figure 22 B,
D). Only TA/BW showed a significant decrease in both TG Non-Ulcerated and TG
Ulcerated when compared to TG muscles (Figure 22 E).

Figure 19 Spleen Cell Dissociation CON and TG: A. CON Tumor spleens showed a significant reduction in T
cell % when compared to CON spleens. B., C. No statistical differences were seen between CD4% or CD8 %
between groups. D. TG Tumor spleens showed a significant reduction in T cell % when compared to TG
spleens. E., F. No statistical differences were seen between CD4% or CD8 % between groups CON (n=8), CON
Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 20 Spleen Dissociation CON and TG: No statistical differences were seen between groups in
NK or NKT cells following spleen dissociation. CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG
Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001

Figure 21 Tumor BW/Volume and Mouse Body mass: A., B., E., F., No statistical differences were seen between
tumor weight or tumor volume in either CON or TG groups. C. Body mass with tumor removed showed a
significant decrease in both CON Non-Ulcerated and CON Ulcerated compared to CON. G. TG Non-Ulcerated body
mass without tumor showed a significant decrease when compared to TG mice. D., H. No statistical differences
were seen between groups with regards to % difference in body mass. CON (n=8), CON Non (n=8), CON Ulc (n=2),
TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001
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Figure 22 Muscle Weights/BW in CON and TG mice: A. TA/BW showed significant decreases in CON NonUlcerated and CON Ulcerated muscles compared to CON muscles. B. Gastroc/BW showed a significant
decrease in CON Non-Ulcerated compared to CON muscles. C. No statistical differences were seen between
Plantaris/BW. D. Quadriceps/BW showed a significant decrease in the CON Non-Ulcerated compared to CON
muscles. E. TA/BW showed significant decreases in TG Non-Ulcerated and TG Ulcerated muscles compared
to TG muscles. F., G., H. No statistical differences were seen between groups. CON (n=8), CON Non (n=8),
CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001
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Chapter 5
General Discussion
Injection of the EO771 mammary tumor cell line into C57BL/6 mice has been
show to induce significant muscle wasting and muscle fatigue. This is verified by
significant decreases in muscle weights as well as body weight, along with the
increased fatigue shown at the 4-week post injection time point (Figure 2,4,7 and 8).
Coinciding with the increased fatigue we showed a decreased mtDNA content (fold
difference) in both 4-week time points suggesting these muscles are fatiguing more than
the CON and 2WK due to less functional mitochondria. Indeed, our lab has shown the
opposite of this where there is an increased mtDNA content via increases in secretion of
IL-15 (23,39). In this model we also show a significant shift in the force frequency
relationship in the EDL muscles of both 4WK Non-Ulcerated and Ulcerated
groups(Figure 3 B) along with lower tetanus forces in both 4 week groups for both EDL
and SOL. This shows that these muscles are not only fatiguing more, but they are
producing greater forces at lower stimulation frequencies indicating overall muscle
dysfunction and a more fatigable phenotype. Along with this we show significant
increases in mRNA content for various biomarkers of atrophy (Murf1 and Atrogin1),
inflammatory markers for cachexia (IL-6 and TNFα) and significant decreases in IL-15
and IL-15 rα which have proposed mechanisms behind mitochondrial biogenesis
(40,41). We also show a significant shift in muscle fiber area in the EDL muscle after
laminin staining in both the 4 week groups, supporting our claim that the muscles weight
less and have a smaller CSA yielding less force and fatiguing at a more rapid rate than
CON of 2WK mice. Our flow cytometry data from our spleen cell isolation did not show
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significant differences; however when comparing just the CON and 2WK groups we saw
a significant decrease in T cell % (Figure 10). The reasoning behind this notion is that
the immune response generated by the cancer can be transient in the perspective of
this study. Indeed, with this timeframe (4 weeks) the tumor has had time to bypass the
immune system and shed potential targeting antigens (31,32). This could lend some
insight as to why our deviations at the 4 week time points are so variable. These data
show that the EO771 cell line induces cancer cachexia and muscle dysfunction
(fatigue), and furthermore is an ideal model to test our proposed therapy of IL-15
skeletal muscle overexpression (Figure 5).
Previous work shows the ability of IL-15 to promote a pro-oxidative/fatigue
resistant phenotype along with increasing overall mitochondrial density (38,40,41,53). It
is by this mechanism that we propose our therapy will prevent the muscular fatigue in
our model. With regards to muscle weights and CSA we saw similarities in the TG
groups showing significant decreases in weight and CSA, coinciding with the
preliminary study. The littermate controls showed a similarities in the CON NonUlcerated groups, however due to a small sample size (n=2) the CON Ulcerated group
did not recapitulate the trend seen in our preliminary work (Figure 10). Looking at the
functionality of the EDL muscle, TG CT and ½ RT showed significant decreases in both
TG Non-Ulcerated and Ulcerated groups signifying alterations in Ca+ handling due to
the systemic effects of the cancer (Figure 11). Again we did not see the same results
represented in our CON groups, we believe this to be due to a small sample size. EDL
muscles from both the CON and TG groups showed a significant decrease in muscle
mass in the Non-Ulcerated and Ulcerated groups for absolute force frequency (Figure
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12). This coincides with our previous study showing the EDL muscle producing less
overall force in tumor bearing mice. Looking at the relative force frequency curve
however, we show no shift in the CON group indicating the muscles are not producing
greater force at lower frequencies which would indicate dysfunction. This is dissimilar to
our preliminary study where, indeed we showed a significant shift in the force frequency
curve. Possible explanations could be attributed to the small sample size, along with
the fact these mice may have not been as severe as our previous study with regards to
tumor burden. SOL muscles for both CON and TG showed a significant reduction in
absolute force frequency similar to EDL muscles, however this was ablated when
looking at relative force frequency. These data highlight the ability of a more oxidative
muscle, even in the absence of IL-15 overexpression (i.e. littermate control) to preserve
overall function in the presence of cancer cachexia. Of note, the SOL maximal tetanus
contraction did show a significant decrease in the CON vs CON ulcerated group.
The major focus on this study was the attenuation of muscle fatigue in the
presence of cancer cachexia. Using our fatigue protocol, we saw a significant shift
down and to the left in force produced throughout our fatigue curve (% force loss) for
both the CON Non-Ulcerated and CON Ulcerated mice vs CON (Figure 14). This shift
was significant for contractions between 20-70 seconds showing a much more rapid
and prolonged fatigue. In comparison, the TG fatigue curve showed a much smaller
shift in Non-Ulcerated and Ulcerated mice, however still significant (Figure1 14). Of
note this fatigue curve started later in the protocol (40 seconds) highlighting the
attenuation of fatigue. It is important to note that these effects happened regardless of
muscle mass loss, considering TG EDL muscles showed similar weight loss to our

56

preliminary study. Another method of analysis was looking at the overall area under the
fatigue curve. We classify this as the total amount of force in mN throughout the 6
minute fatigue protocol. We see there was a significant reduction in area under the
fatigue comparing the CON and CON Non-Ulcerated mice. This reinforces the idea that
there is an increased fatigue in these mice (Figure 15). Again if we had more mice in
the CON Ulcerated group we feel that we would have reached significance considering
our preliminary study. Looking at the TG area under the fatigue curve we show no
differences between groups, further exemplifying the attenuation of fatigue in these
mice (Figure 15). These data suggest IL-15 has the ability to promote a fatigue
resistant phenotype, attenuating overall fatigue experienced in cancer cachexia
settings. When looking at the more oxidative muscle (SOL) we saw no significant
differences in relative fatigue between either CON for TG groups, again showing
preservation of function in a more mitochondrial dense muscle (Figure 16).
When we imaged these mice we saw a slight trend towards overall reduction of
size in tumors of the TG groups, however it was not significant. IL-15 has been shown
to promote overall immune function and cell cytotoxicity when treating cancer patients in
clinical trials (54-56). However, previous work with this cell line has shown that the
immunosuppressive nature of EO771 tumors can make it a challenging model to test
immune based therapies (57). We showed a trend with reduction of tumor burden in the
TG injected mice looking at tumor volume and IVIS bioluminescence, however there
was no significance (Figure 17). Furthermore, we showed no statistical differences
between the CON Tumor and TG Tumor following dissociation looking at different
immune cells (CD4 Helper T, CD8 Cytotoxic T, NK1.1, NKT) (Figure 18). With the
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spleen cell dissociation, we did show a significant reduction in T cells in the CON Tumor
and TG Tumor when compared to their respective controls, however no other stains
showed any significant differences (Figure 19 and 20). We attribute this to the
immunosuppressive nature of this tumor type (57) as well as the tumors ability at this
point to bypass any immune response. Further studies should be done looking at
sooner time points (2WK) which would give us a better scope of the immune response
with IL-15 treatment. Looking at overall tumor burden (weight/volume) we did not show
any statistical differences between Non-Ulcerated or Ulcerated groups for either CON or
TG mice (Figure 21 A, B, E, F). This could be a sample size issue considering the CON
Ulcerated group had n=2 and the TG Ulcerated had N=4. We did show that the body
mass of CON mice with the tumor removed was significantly lower in the CON NonUlcerated and CON Ulcerated, along with a large difference in body mass in the CON
Ulcerated groups, however not significant (Figure 21 C,D). We did show a significant
reduction in the TG Non-Ulcerated mass with tumor removed when compared to TG
uninjected and we felt significance would be reached in the TG Ulcerated group if we
increased the sample size (Figure 21). Tibialis Anterior muscle dissection is the most
accurate and precise dissection next to EDL and SOL muscles. In the TA we showed
significant reduction in CON Non-Ulcerated and CON Ulcerated weights compared to
CON as well as significant reduction in TG Non-Ulcerated and TG Ulcerated compared
to TG (Figure 22). These data combine with our previous measurements show an
overall decrease in muscle weight with the presence of cancer.
While we did not show differences in immune function, we were able to attenuate
muscle fatigue in the presence of cancer due to IL-15 skeletal muscle overexpression.
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These effects can be very translational due to IL-15 testing already taking place in
clinical trials for improving immune function in cancer patients (7,54-56). With this in
mind IL-15 can be proposed as an effective dual immune/fatigue therapy by primarily
targeting improvements in immune function all while attenuation skeletal muscle fatigue
seen in cancer cachexia patients. This becomes crucial when treatment of the cancer
takes place. With chemotherapy potentially exacerbating cachexia, the ability to
attenuate fatigue and improve immune response will likely lead to a faster recovery and
decreased morbidity and mortality.
The next step for this project would be the addition of mice to both 4WK
Ulcerated groups. This would give us an overall even number in each group, potentially
allowing our littermate control data to recapitulate our preliminary research. Additionally
we plan to dissociate more tumors in the 4WK groups, as well as establishing a 1 and 2
week time point. We feel the addition of these groups will potentially lead to our further
understanding of the effects IL-15 has in the immune response in our particular model.
Our next proposed step would be the administration of IL-15 via osmotic mini
pump. After a preliminary trial using an IL-15 administered group (n=2) and a sham
groups given sterile PBS (n=2) we were able to perform a sterile surgery and have mice
survive to the 4 week time point. Moving forward we plan to repeat the protocol both
addressing different dose dependent alterations in muscle function and immune cell
populations, but also identifying any toxic or inflammatory responses associated with
this method of administration. Indeed, previous work in cancer patients who were
administered human IL-15 showed positive responses in CD8 T cell and NK cell activity.
Higher doses however, were also associated with increased toxicity and a larger
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inflammatory response (55). This will allow us to identify a dose that will produce the
best response in attenuating muscle fatigue. Following this we can scale up dosing to
address muscle fatigue in a clinical setting of cancer cachexia
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Chapter 5

Methodology
6.1
Mice
C57BL6WT mice were purchased from The Jackson Laboratory (n=23) and randomly
assigned to a control group (Control; n=8), mice that were euthanized following 2 weeks
of tumor growth (2WK, n=5), and mice that were euthanized following 4 weeks of tumor
growth (4WK, n=10). The 4WK group was subsequently divided into mice that
developed an ulcerated tumor (4WK-UT; n=6) and mice that developed a non-ulcerated
tumor (4WK-NUT; n=4). IL-15 TG muscle overexpressor mice were purchased from
Jackson Laboratory and bred yielding IL-15 TG overexpressor pups and littermate
controls, which were used for the subsequent experiment. Mice were split into six
groups; a control uninjected group (CON=8), a control Ulcerated group (CON NonUlcerated=8), a Control Ulcerated group (CON Ulcerated= 2), a transgenic group
(TG=7), a transgenic Non-Ulcerated group (TG Non-Ulcerated=7) and transgenic
Ulcerated group (TG Ulcerated=4) Mice were housed in the animal vivarium at West
Virginia University at 22°C under a 12:12-h light-dark cycle and received food and water
ab libitum. All animal experiments were approved by the Institutional Animal Care and
Use Committee at West Virginia University.

6.2
E0771 Murine Breast Cancer Cells
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The E0771 cell line used in these studies was kindly provided by Linda MetheneyBarlow (Wake Forest) E0771 cells were cultured using aseptic technique and
maintained under standard mammalian culture conditions (37ºC, 99% humidity, 5%
CO2). Cells were maintained in high glucose DMEM supplemented with 10% FBS to
maintain active proliferation. Cells were passed via trypsinization using 0.25%
trypsin/EDTA in Hanks buffered saline solution (Gibco). Cells were grown until ~90%
confluent at which time they were prepped for injection. Cells were trypsinized and
resuspended in sterile PBS. A cell count was performed yielding 1 million cells per
100µL injection into the 4th nipple (mammary fat pad) of female C57BL6WT mice and
IL-15 TG mice.

6.3
Muscle Physiology on EDL and SOL Muscle in C57BL6WT mice and IL-15 TG
overexpression mice.
Female mice were deeply anesthetized by breathing 4% isoflurane delivered through a
nose cone at a flow rate of 1 l/min. Muscles were removed with both proximal and distal
tendons intact, and nylon sutures were attached to the tendons. Muscles were
transferred to an oxygenated tissue bath that contained Ringer solution (100 mM NaCl,
4.7 mM KCl, 3.4 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, and
5.5 mM D-glucose) maintained at 22°C. Ex vivo muscle stimulation was performed
using a commercially available muscle physiology system (Aurora Scientific, Ontario,
CA). Muscle length was adjusted to obtain the maximal twitch response (i.e., Lo). Three
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twitch contractions were performed all separated by 2 min. Parameters analyzed from
isometric contractions included peak isometric twitch force (Pt), time to peak twitch
tension (TPT), half-relaxation time of twitch contraction (½ RT), and peak isometric
tetanic force (Po). Isometric tetanic contractions were stimulated in muscles at a
stimulation frequency of 120 Hz for EDL muscles and 80 Hz for soleus muscles, a
stimulation current of 20 V, and lasting 500 ms. Following isometric contractions, the
muscles remained in oxygenated Ringer’s for 5 minutes prior to the repeatedstimulation fatigue protocol. Muscle fatigue was analyzed using a repeated stimulation
protocol lasting 6 min and consisting of repeated 40-Hz tetanic trains that occurred once
every second and lasted 330 ms.

6.4
Muscle Morphology
Due to our previous reports showing a decrease in fiber area with progression of cancer
cachexia EDL and SOL muscles will be flash frozen in isopentane cooled to the
temperature of liquid nitrogen and stored at –80°C. Serial frozen sections (10 μm thick)
of EDL and SOL muscles were obtained using a cryostat at −21°C and placed onto
glass slides (Superfrost/Plus, Fisher Scientific). Sections were stained with Alexa
Flour® 488-conjugate AffiniPure Goat Anti-Rabbit IgG (Jackson ImmunoResearch
Labratories, INC) and ANTI-LAMININ Affinity Isolated Antigen Specific
Antibody(SIGMA-ALDRICH®) and then mounted with 4’,6-diamidino-2-phenylindole
(DAPI) mounting medium (Vector Laboratories, Burlingham, CA). Similar Analysis will
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be performed using the Image Process & Analysis Workstation in the CORES Facility,
utilizing the Muscle Fiber General Analysis protocol.

6.5
Mitochondrial DNA content
Total DNA (genomic and mitochondrial) will be extracted from tibialis anterior (TA)
muscles from female mice using a DNeasy Blood and Tissue kit (Qiagen, Valencia, CA)
and quantified using a Nano-Drop spectrophotometer (ThermoScientific, Waltham, MA).
TaqMan primers for mitochondrial DNA-encoded cytochrome-c oxidase subunit II
(COXII) and nuclear-encoded 18S ribosomal RNA will be used to perform real-time
qPCR. The wells of a 96-well optical reaction plate were loaded with a 20-μl volume
consisting of TaqMan 10X PCR Master Mix, a primer mix for either the mitochondrialencoded gene or the nuclear-encoded gene, and DNA diluted to a concentration of 5
ng/μl. Each DNA sample was analyzed in pairs and amplified in an Applied Biosystems
7900HT Fast Real-Time PCR system. The cycle threshold (CT) values of the
mitochondrial-encoded COXII gene and the nuclear-encoded 18S gene in muscles
C57BL6 WT mice were used to quantify the fold change using the ΔΔCT calculation
(58)

6.6
RNA Isolation and PCR
Total RNA will be isolated using Trizol reagent (Life Technologies, Grand Island, NY),
as previously described (59). RNA quantity and quality will be assessed using a Nano-
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Drop 2000 spectrophotometer (ThermoScientific, Waltham, MA); the 260/280 ratio for
all samples used was between 1.8 and 2.1. Two micrograms of total RNA will be
reverse transcribed to make cDNA using a high-capacity reverse transcription kit
according to manufacturer's instructions (Life Technologies, Grand Island, NY).
Amplification was performed in a reaction consisting of 8.5 μl nuclease-free H2O, 12.5
μl 2X Taq-Pro Red Complete 1.5 mM MgCl2 master mix (Denville Scientific, Metuchen,
NJ), 1.0 μl forward primer, 1.0 μl reverse primer, and 2 μl of DNA template to make a 25
μl total reaction volume. Primers were constructed from published sequences. Primer
pairs for IL-15, IL-15 rα, IL-6, TNFα, Grim19, Murf1 and Atrogin-1 were coamplified with
primer pairs for 18S (Ambion, Austin, TX). The number of PCR cycles was determined
in preliminary experiments to ensure analyses were done in the linear range of
amplification. Following amplification, each reaction will be visualized following gel
electrophoresis in 1% (wt/vol) agarose gels stained with ethidium bromide. PCR bands
were quantified using the ImageJ software program (http://rsbweb.nih.gov/ij/). Signals
for the gene of interest were normalized to the bands for 18S that were amplified in the
same reaction.

6.7
Spleen Cell Isolation
Single cell suspensions from the spleen and of each mouse were extracted and a single
cell suspension of 1 million cells will be generated following cell isolation, red blood cell
lysing and washing steps (1.5% FBS RPMI). Staining will comprise of CD3 (generalized
T cell marker), CD4 (Helper T cell marker), CD8 (Cytotoxic T cell) and Natural Killer cell
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staining (NK). T cell count will be gated to a CD45 cell surface marker antibody. Flow
data gives us a representative image of the percent of cells in solution.

6.8
Tumor Dissociation
Tumors will be dissected away from mice and homogenized using the MACS tissue
dissociator. (MACS Miltenyi Biotec). Following dissociation cells will be strained and
the red blood cells with be lysed. Following a period of wash steps similar to the spleen
cell isolation, 1 million cells will be collected and stained for flow cytometry. Staining will
comprise of CD3 (generalized T cell marker), CD4 (Helper T cell marker), CD8
(Cytotoxic T cell) and Natural Killer cell staining (NK). T cell count will be gated to a
CD45 cell surface marker antibody. Flow data will give us a representative image of
the percent of cells in solution.

6.9
IVIS Imagine and Tumor Burden
Imaging of each mouse will take place once a week in the Animal Facility. A luciferase
injection will be administered so the EO771 cells illuminate during recording. Mice will
be anesthetized by breathing 4% isoflurane delivered through a nose cone at a flow rate
of 1 l/min. The subsequent images generated from this will be analyzed looking at tumor
growth and total flux score.

6.10
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VEVO Tumor Volume
Following IVIS Imaging, mice will be transferred to the VEVO Ultrasound room.
Mice will be anesthetized by breathing 4% isoflurane delivered through a nose cone at a
flow rate of 1 l/min. Tumor volume will be measured using ultrasound (Visual Sonics)
and tumor volumes calculated from these data.

6.11
Data Collection
Statistical analysis was performed using GraphPad Prism 5 software. Data will be
reported as mean ± SEM, using ANOVA statistical analysis between experimental
groups and student t-test where applicable.

6.12
Animal Care
Mice were housed in the Animal Resources Department of West Virginia University
School of Medicine in compliance with the NIH and the Institutional Animal Care and
Use Committee guidelines. Animals are attended by a full-time veterinary and support
staff. Unless noted otherwise, the animals are house in a pathogen-free environment,
receive food and water ad libitum, and receive standard care daily.
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Chapter 8
Supplemental Data

Supplemental 1 EDL and SOL Fiber Distribution: A. EDL CON Fiber Area showed a shift in both
the CON Non-Ulcerated and CON Ulcerated groups compared to CON muscles. B. No
differences were seen in SOL CON Fiber Area. C. No differences were seen in the EDL TG Fiber
Area. D. No differences were seen in the SOL TG Fiber Area

77

Supplemental 2: A. EDL absolute mass showing significant decreases in both 4 week groups compared to
CON and 2WK, ELD mass normalized to body mass without the tumor showed significant decreases in both
4 week groups compared to CON mice. B. Absolute Soleus mass showed significant decreases in the 4
week Ulcerated groups compared to CON. C. TA absolute mass showed significant decreases in both 4
week groups compared to CON and 2 week, TA mass normalized to body mass without the tumor showed
significant decreases in both 4 week groups compared to CON and 2 week. D. Gastrocnemius absolute
mass showed significant decreases in both 4 week groups compared to CON and 2 week. E. Hear mass
normalized to body mass without the tumor showed a significant increase in 4 week ulcerated mass
compared to CON and 2 week. F. Both Absolute and normalized to body mass without the tumor weights
of the spellen showed significant increases in the 4 week groups compared to the CON and 2 week groups

